肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：GABBR2可以作为EGFR19缺失肺腺癌的治疗靶点

2017-09-05 MedSci MedSci原创

肺腺癌EGFR19GABBR2
关注

过去的几十年中，人们见证了 个体化靶向治疗肺癌的快速进展。但是EGFR突变肺癌对TKI治疗的反应是否涉及到遗传学改变尚不清楚。CLIN CANCER RES近期发表了一篇文章，研究了这个问题。

过去的几十年中，人们见证了 个体化靶向治疗肺癌的快速进展。但是EGFR突变肺癌对TKI治疗的反应是否涉及到遗传学改变尚不清楚。CLIN CANCER RES近期发表了一篇文章，研究了这个问题。

作者检测了出现部分反应的EGFR19缺失的Ⅲa期肺腺癌患者在接受厄洛替尼治疗前和治疗后42天的肿瘤组织标本。针对上调或下调的潜在靶点基因进行研究，以期阐明厄洛替尼治疗反应的调节机制。研究结果证实了两个异常的甲基化基因CBFAT2T3和GABBR2起到的作用。GABBR2基因exon2和exon3之间的差异性甲基化区域在患者中得到确认。在EGFR19缺失的细胞系HCC4006和HCC827中，GABBR2显着下调，但是在厄洛替尼治疗后的EGFR野生型A549细胞中保持不变。在HCC827细胞中，GABBR2表达上调显着改善厄洛替尼诱导的细胞凋亡。GABBR2显着下调时同时观察到S6，p-p70 S6以及p-ERK1/2减少，表明GABBR2通过 ERK1/2通路在EGFR信号传导中起到了重要作用。

文章最后认为，GABBR2基因可以作为EGFR19缺失的Ⅲa期肺腺癌厄洛替尼诱导治疗后的潜在基因治疗靶点。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=280482, encodeId=fc77280482f7, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/8F614D4C7782A43FC285DED9FF682889/100, createdBy=b4a62141201, createdName=Yahaha, createdTime=Sat Jan 20 22:24:24 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895343, encodeId=44be18953432d, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Oct 05 00:39:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Sep 07 04:39:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240875, encodeId=38a82408e54f, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:53 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240833, encodeId=791a240833c9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:46:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240766, encodeId=6ef9240e663c, content=学习了.TKI的机制又更清楚了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo1pakLFUEWD4aw9tDzG7UDuyJKicLYyJtiaVNfiaY3JfcSoCYagoEiaoq6eh09qnrgoGCZQqfl5eo1KQ/0, createdBy=fed0100583, createdName=vicjaychou, createdTime=Tue Sep 05 15:25:32 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-01-20 Yahaha

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=280482, encodeId=fc77280482f7, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/8F614D4C7782A43FC285DED9FF682889/100, createdBy=b4a62141201, createdName=Yahaha, createdTime=Sat Jan 20 22:24:24 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895343, encodeId=44be18953432d, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Oct 05 00:39:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Sep 07 04:39:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240875, encodeId=38a82408e54f, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:53 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240833, encodeId=791a240833c9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:46:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240766, encodeId=6ef9240e663c, content=学习了.TKI的机制又更清楚了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo1pakLFUEWD4aw9tDzG7UDuyJKicLYyJtiaVNfiaY3JfcSoCYagoEiaoq6eh09qnrgoGCZQqfl5eo1KQ/0, createdBy=fed0100583, createdName=vicjaychou, createdTime=Tue Sep 05 15:25:32 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-10-05 drj2003

    #治疗靶点#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=280482, encodeId=fc77280482f7, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/8F614D4C7782A43FC285DED9FF682889/100, createdBy=b4a62141201, createdName=Yahaha, createdTime=Sat Jan 20 22:24:24 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895343, encodeId=44be18953432d, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Oct 05 00:39:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Sep 07 04:39:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240875, encodeId=38a82408e54f, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:53 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240833, encodeId=791a240833c9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:46:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240766, encodeId=6ef9240e663c, content=学习了.TKI的机制又更清楚了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo1pakLFUEWD4aw9tDzG7UDuyJKicLYyJtiaVNfiaY3JfcSoCYagoEiaoq6eh09qnrgoGCZQqfl5eo1KQ/0, createdBy=fed0100583, createdName=vicjaychou, createdTime=Tue Sep 05 15:25:32 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-07 liuyiping

    #GFR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=280482, encodeId=fc77280482f7, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/8F614D4C7782A43FC285DED9FF682889/100, createdBy=b4a62141201, createdName=Yahaha, createdTime=Sat Jan 20 22:24:24 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895343, encodeId=44be18953432d, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Oct 05 00:39:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Sep 07 04:39:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240875, encodeId=38a82408e54f, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:53 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240833, encodeId=791a240833c9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:46:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240766, encodeId=6ef9240e663c, content=学习了.TKI的机制又更清楚了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo1pakLFUEWD4aw9tDzG7UDuyJKicLYyJtiaVNfiaY3JfcSoCYagoEiaoq6eh09qnrgoGCZQqfl5eo1KQ/0, createdBy=fed0100583, createdName=vicjaychou, createdTime=Tue Sep 05 15:25:32 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 忠诚向上

    好好看下.内容丰富

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=280482, encodeId=fc77280482f7, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/8F614D4C7782A43FC285DED9FF682889/100, createdBy=b4a62141201, createdName=Yahaha, createdTime=Sat Jan 20 22:24:24 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895343, encodeId=44be18953432d, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Oct 05 00:39:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Sep 07 04:39:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240875, encodeId=38a82408e54f, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:53 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240833, encodeId=791a240833c9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:46:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240766, encodeId=6ef9240e663c, content=学习了.TKI的机制又更清楚了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo1pakLFUEWD4aw9tDzG7UDuyJKicLYyJtiaVNfiaY3JfcSoCYagoEiaoq6eh09qnrgoGCZQqfl5eo1KQ/0, createdBy=fed0100583, createdName=vicjaychou, createdTime=Tue Sep 05 15:25:32 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 luominglian113

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=280482, encodeId=fc77280482f7, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/8F614D4C7782A43FC285DED9FF682889/100, createdBy=b4a62141201, createdName=Yahaha, createdTime=Sat Jan 20 22:24:24 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895343, encodeId=44be18953432d, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Oct 05 00:39:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Sep 07 04:39:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240875, encodeId=38a82408e54f, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:53 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240833, encodeId=791a240833c9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:46:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240766, encodeId=6ef9240e663c, content=学习了.TKI的机制又更清楚了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo1pakLFUEWD4aw9tDzG7UDuyJKicLYyJtiaVNfiaY3JfcSoCYagoEiaoq6eh09qnrgoGCZQqfl5eo1KQ/0, createdBy=fed0100583, createdName=vicjaychou, createdTime=Tue Sep 05 15:25:32 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 vicjaychou

    学习了.TKI的机制又更清楚了

    0

相关资讯

SCI REP：伴COPD的肺腺癌患者LRP1B突变率更高

慢性阻塞性肺病（COPD）以及肺癌是常见的肺部疾病，常共同发生。有研究表明COPD会增加肺癌发生的风险，这一现象表明COPD与肺癌发生之间存在着某种联系。人们提出了多种理论如氧化应激、遗传易感性、表观遗传学改变、炎性环境改变等来联系COPD与肺癌，但是COPD与肺癌发生之间联系的分子机制尚不明确。

Plos One：预测培美曲塞加铂类对晚期肺腺癌患者疗效的新方法！

目前，虽然培美曲塞加顺式/卡铂已经成为晚期肺腺癌患者最有效的化疗方案，但是，相关预测性生物标志物尚不可用，因此，迫切需要一项能够鉴定潜在受益于此治疗方案的敏感性患者的新工具。近期，一项发表在杂志Plos One上的研究使用两个数据库中的血清肽图谱构建并验证了预测肽模型。此项研究回顾性分析了使用以铂类为基础联合培美曲塞作为一线治疗的138例晚期肺腺癌患者，并随机分入构建组（n = 92）或验证组（n

EBioMedicine：昆医学者发现他汀能预防肺腺癌骨转移

2017年4月，昆明医科大学第三附属医院骨科（云南省骨与软组织肿瘤诊治研究中心）杨祚璋教授、东南大学医学院苏振毅博士、美国哈佛医学院Judy Park DeWitt博士以共同第一作者在由The Lancet和Cell合作主办的《EBioMedicine》杂志上发表最新研究成果：“Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by

J Thorac Oncol:病灶≤3cm、淋巴结阴性根治性手术肺腺癌的预后因素分析

目前多个有关NSCLC的指南，都没建议病灶≤3cm、淋巴结阴性肺癌根治性手术后行辅助化疗。而关于这一类肿瘤的不同组织亚型，不同形态特征及不同病灶大小亚群的各自预后情况，目前相关研究也较少。最近，台北荣民总医院洪荣志等在Journal of Thoracic Oncology发文，对这一问题进行了探讨。

J Natl Cancer Inst ：美研究显示“轻型”香烟会增加患肺腺癌风险

据美国“侨报网”5 月 22 日报道，一项发表在《国家癌症研究所杂志》(the Journal of the National Cancer Institute)上的研究表明，所谓的“轻型”香烟不仅有害健康，还可能导致患肺腺癌 (肺癌的一种) 的风险增加。

Cancer Res：揭示肺癌成功转移到大脑中的分子机制

每年因肺癌死亡的人要远远多于因乳腺癌、结肠癌以及前列腺癌死亡的人数，肺癌的一种特殊致死性形式是肺腺癌（LUAD），其影响着吸烟和非吸烟人群的健康，在很多被诊断为肺腺癌的患者中，其机体中的肿瘤细胞已经扩散到了大脑中，这样就会明显降低患者的生活质量以及生存率。 日前，一项刊登在国际杂志